[
  {
    "ts": null,
    "headline": "Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study",
    "summary": "MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.",
    "url": "https://finnhub.io/api/news?id=bb6687e954cd20b8677e280f31cd015f6e63b9d57035bcce6361882ab0675c4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732651200,
      "headline": "Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study",
      "id": 131654141,
      "image": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.",
      "url": "https://finnhub.io/api/news?id=bb6687e954cd20b8677e280f31cd015f6e63b9d57035bcce6361882ab0675c4c"
    }
  },
  {
    "ts": null,
    "headline": "Strategic ETF Allocations: Enhancing Income, Diversification, And Reducing Risks In Your Dividend Portfolio",
    "summary": "I added shares of Schwab U.S. Dividend Equity ETF and the Cohen & Steers Quality Income Realty Fund to The Dividend Income Accelerator Portfolio. Find out why.",
    "url": "https://finnhub.io/api/news?id=4bd575a3a62c82f7dc3d88336460a079baf676a9afffba1e7e5bc0a85e3f433c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732644000,
      "headline": "Strategic ETF Allocations: Enhancing Income, Diversification, And Reducing Risks In Your Dividend Portfolio",
      "id": 131653691,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159094952/image_2159094952.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "I added shares of Schwab U.S. Dividend Equity ETF and the Cohen & Steers Quality Income Realty Fund to The Dividend Income Accelerator Portfolio. Find out why.",
      "url": "https://finnhub.io/api/news?id=4bd575a3a62c82f7dc3d88336460a079baf676a9afffba1e7e5bc0a85e3f433c"
    }
  },
  {
    "ts": null,
    "headline": "How To Put $100 In Your Retirement Fund Each Month With Johnson & Johnson",
    "summary": "Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide. It will report its Q4 2024 earnings on Jan. 22, 2025. Wall Street analysts expect the company to post an EPS of $2.29, ...",
    "url": "https://finnhub.io/api/news?id=08117ae2006e41ef72c887bd22b111666386b3523534caa3dd4d863f16b23693",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732640412,
      "headline": "How To Put $100 In Your Retirement Fund Each Month With Johnson & Johnson",
      "id": 131650956,
      "image": "https://media.zenfs.com/en/benzinga_79/73a49ddd148c07d14880686b58ca933b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide. It will report its Q4 2024 earnings on Jan. 22, 2025. Wall Street analysts expect the company to post an EPS of $2.29, ...",
      "url": "https://finnhub.io/api/news?id=08117ae2006e41ef72c887bd22b111666386b3523534caa3dd4d863f16b23693"
    }
  },
  {
    "ts": null,
    "headline": "Investors in Johnson & Johnson (NYSE:JNJ) have seen decent returns of 30% over the past five years",
    "summary": "The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...",
    "url": "https://finnhub.io/api/news?id=8d0025bf7415bde66a832109205a8571fd39b737a4b6c4828fc287fa251c451d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732629632,
      "headline": "Investors in Johnson & Johnson (NYSE:JNJ) have seen decent returns of 30% over the past five years",
      "id": 131650957,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/2eedc463aef15274c4887c130e30e298",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...",
      "url": "https://finnhub.io/api/news?id=8d0025bf7415bde66a832109205a8571fd39b737a4b6c4828fc287fa251c451d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists",
    "summary": "Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That's why they joined Johnson & Johnson's That's...",
    "url": "https://finnhub.io/api/news?id=5c6932bc115354d5ad7cc53c1453ad30555b466532fe5d9907f9568fca70033c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732616834,
      "headline": "Johnson & Johnson - After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists",
      "id": 131638394,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That's why they joined Johnson & Johnson's That's...",
      "url": "https://finnhub.io/api/news?id=5c6932bc115354d5ad7cc53c1453ad30555b466532fe5d9907f9568fca70033c"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi joins J&J, Eli Lilly in proposing 340B rebate model",
    "summary": "Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year. It’s unclear how regulators will react.",
    "url": "https://finnhub.io/api/news?id=e2c65ac9a348b840b930a39a7012da58ed464b06cd0a27aa83990a0910bc9bc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732611780,
      "headline": "Sanofi joins J&J, Eli Lilly in proposing 340B rebate model",
      "id": 131643474,
      "image": "https://imgproxy.divecdn.com/sJde9s13htXdbDYTH8JFwHQXqK8elE4ovKg0CluPAZ8/g:nowe:0:87/c:520:294/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDE4OTA3MTU1XzEuanBn.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year. It’s unclear how regulators will react.",
      "url": "https://finnhub.io/api/news?id=e2c65ac9a348b840b930a39a7012da58ed464b06cd0a27aa83990a0910bc9bc3"
    }
  },
  {
    "ts": null,
    "headline": "Is Johnson & Johnson (JNJ) the Best Dividend Aristocrat Stock To Buy Right Now?",
    "summary": "We recently compiled a list of the 10 Best Dividend Aristocrat Stocks To Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other dividend aristocrat stocks. Investors usually buy stocks with the expectation that their value will increase as the company grows more […]",
    "url": "https://finnhub.io/api/news?id=dd80dd384548e224ad8556d0cdde32ec8cae31f45cadd7fc33e898734bdfb9a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732609045,
      "headline": "Is Johnson & Johnson (JNJ) the Best Dividend Aristocrat Stock To Buy Right Now?",
      "id": 131631292,
      "image": "https://s.yimg.com/ny/api/res/1.2/DBFyZ0OZ_JyFkP8R8eQoiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Best Dividend Aristocrat Stocks To Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other dividend aristocrat stocks. Investors usually buy stocks with the expectation that their value will increase as the company grows more […]",
      "url": "https://finnhub.io/api/news?id=dd80dd384548e224ad8556d0cdde32ec8cae31f45cadd7fc33e898734bdfb9a6"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Equity And Income Fund Q3 2024 Commentary",
    "summary": "The fund holds high-grade bonds and convertible securities as a source of income and to help provide a measure of stability in volatile markets.",
    "url": "https://finnhub.io/api/news?id=87ab91299af1405d674e3167edc6d5195c32df8775ce32d0e978e4c48282122f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732602300,
      "headline": "Invesco Equity And Income Fund Q3 2024 Commentary",
      "id": 131631071,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1562199023/image_1562199023.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The fund holds high-grade bonds and convertible securities as a source of income and to help provide a measure of stability in volatile markets.",
      "url": "https://finnhub.io/api/news?id=87ab91299af1405d674e3167edc6d5195c32df8775ce32d0e978e4c48282122f"
    }
  }
]